Kambale Espoir K, Quetin-Leclercq Joëlle, Memvanga Patrick B, Beloqui Ana
Advanced Drug Delivery and Biomaterials Group, Louvain Drug Research Institute, UCLouvain, Université Catholique de Louvain, Avenue Mounier 73, B1.73.12, 1200 Brussels, Belgium.
Laboratory of Pharmaceutics and Phytopharmaceutical Drug Development, Faculty of Pharmaceutical Sciences, University of Kinshasa, B.P. 212, Kinshasa 012, Democratic Republic of the Congo.
Pharmaceutics. 2022 Oct 8;14(10):2135. doi: 10.3390/pharmaceutics14102135.
Diabetes is a metabolic pathology with chronic high blood glucose levels that occurs when the pancreas does not produce enough insulin or the body does not properly use the insulin it produces. Diabetes management is a puzzle and focuses on a healthy lifestyle, physical exercise, and medication. Thus far, the condition remains incurable; management just helps to control it. Its medical treatment is expensive and is to be followed for the long term, which is why people, especially from low-income countries, resort to herbal medicines. However, many active compounds isolated from plants (phytocompounds) are poorly bioavailable due to their low solubility, low permeability, or rapid elimination. To overcome these impediments and to alleviate the cost burden on disadvantaged populations, plant nanomedicines are being studied. Nanoparticulate formulations containing antidiabetic plant extracts or phytocompounds have shown promising results. We herein aimed to provide an overview of the use of lipid- and inorganic-based nanoparticulate delivery systems with plant extracts or phytocompounds for the treatment of diabetes while highlighting their advantages and limitations for clinical application. The findings from the reviewed works showed that these nanoparticulate formulations resulted in high antidiabetic activity at low doses compared to the corresponding plant extracts or phytocompounds alone. Moreover, it was shown that nanoparticulate systems address the poor bioavailability of herbal medicines, but the lack of enough preclinical and clinical pharmacokinetic and/or pharmacodynamic trials still delays their use in diabetic patients.
糖尿病是一种代谢性疾病,其特征为慢性高血糖,当胰腺分泌的胰岛素不足或身体不能正常利用所分泌的胰岛素时就会发生。糖尿病的管理是一个难题,重点在于健康的生活方式、体育锻炼和药物治疗。到目前为止,这种疾病仍然无法治愈;管理措施只是有助于控制病情。其医疗费用高昂且需要长期治疗,这就是为什么人们,尤其是来自低收入国家的人们,会求助于草药。然而,许多从植物中分离出的活性化合物(植物化合物)由于其低溶解度、低渗透性或快速消除而生物利用度较差。为了克服这些障碍并减轻弱势群体的成本负担,人们正在研究植物纳米药物。含有抗糖尿病植物提取物或植物化合物的纳米颗粒制剂已显示出有前景的结果。我们在此旨在概述基于脂质和无机的纳米颗粒递送系统与植物提取物或植物化合物在糖尿病治疗中的应用,同时强调它们在临床应用中的优点和局限性。综述研究的结果表明,与单独的相应植物提取物或植物化合物相比,这些纳米颗粒制剂在低剂量下具有较高的抗糖尿病活性。此外,研究表明纳米颗粒系统解决了草药生物利用度差的问题,但缺乏足够的临床前和临床药代动力学和/或药效学试验仍然延迟了它们在糖尿病患者中的应用。